Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies.

Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored.

Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers.

Method: Retrospective and prospective monocentric cohort study

Eligibility criteria

Qualifiers

Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma

Cytologically or histologically proven adenocarcinoma, regardless of stage and treatment

Age ≥ 18 years old

Diagnosed from 2015 onwards

Disqualifiers

Patient under guardianship, curatorship or safeguarding of justice

Pregnant or breastfeeding woman

Any medical, psychological or social situation that could prevent compliance with the protocol according to the investigator's assessment.

Refusal to participate in the study

Trial design

Treatments tested in this trial

  • Tumor samples

Treatment groups

200 Participants
are divided into 1 treatment group

Locations

This trial has no locations